{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:10:46Z","timestamp":1793128246796,"version":"4.5.0"},"reference-count":191,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Colorectal cancer (CRC) with a deficient mismatch repair and high microsatellite instability (dMMR\u2013MSI-H) phenotype represents a biologically distinct subtype characterized by elevated tumor mutational burden and strong immunogenicity. These features contribute to their exceptional responsiveness to immune checkpoint inhibitors (ICIs), especially those targeting the PD-1 and CTLA-4 pathways. Although dMMR\u2013MSI-H tumors constitute only a small fraction of CRC cases, their response to ICIs has redefined therapeutic standards. In this review, we discuss the immunological underpinnings that render these tumors susceptible to immune modulation, summarize key clinical trial findings, and analyze emerging resistance mechanisms. Furthermore, we highlight the evolving landscape of predictive biomarkers and ongoing efforts to increase treatment efficacy through combination strategies and biomarker-driven approaches.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1828717","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:06:17Z","timestamp":1782918377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects"],"prefix":"10.3389","volume":"17","author":[{"given":"Guangre","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of anorectal surgery, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of pediatric surgery, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.12.003","article-title":"Tumor \"age\" in early-onset colorectal cancer","volume":"188","author":"Mauri","year":"2025","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105142","article-title":"Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms","volume":"103","author":"Xu","year":"2024","journal-title":"EBioMedicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-2213","article-title":"Biomarkers of pathologic complete response to neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer","volume":"30","author":"Li","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2226418","article-title":"Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer","volume":"24","author":"Huang","year":"2023","journal-title":"Cancer Biol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-020-00464-y","article-title":"New first-line therapy for dMMR\/MSI-H CRC","volume":"18","author":"Romero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad775","article-title":"DNA mismatch repair protects the genome from oxygen-induced replicative mutagenesis","volume":"51","author":"Lozsa","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02691","article-title":"Mismatch repair-deficient colorectal cancer: building on checkpoint blockade","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3031","article-title":"Hypermutation, mismatch repair deficiency, and defining predictors of response to checkpoint blockade","volume":"27","author":"Graham","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad082","article-title":"BRAF V600E\/RAS mutations and Lynch syndrome in patients with MSI-H\/dMMR metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"28","author":"Colle","year":"2023","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.449","article-title":"DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer","volume":"29","author":"Worthley","year":"2010","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311403","article-title":"Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database","volume":"66","author":"Moller","year":"2017","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3878","article-title":"Milestones of lynch syndrome: 1895-2015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.07.002","article-title":"Tumor-agnostic drug development in dMMR\/MSI-H solid tumors","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4342","article-title":"Mismatch repair and microsatellite testing for individuals with colorectal cancer","volume":"10","author":"Dhimal","year":"2024","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2023.05.004","article-title":"Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes","volume":"260","author":"Hajkova","year":"2023","journal-title":"Transl Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.120","article-title":"Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation","volume":"5","author":"McCarthy","year":"2019","journal-title":"J Pathol Clin Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.217","article-title":"Differences and evolution of the methods for the assessment of microsatellite instability","volume":"27","author":"Laghi","year":"2008","journal-title":"Oncogene"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2257133","article-title":"External quality assessment for the molecular detection of microsatellite instability in China, 2021-2022","volume":"23","author":"Fan","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"key":"B29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","article-title":"Clinical cancer genomic profiling","volume":"22","author":"Chakravarty","year":"2021","journal-title":"Nat Rev Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein","year":"2014","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-019-0241-1","article-title":"Biomarker-guided therapy for colorectal cancer: strength in complexity","volume":"17","author":"Sveen","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41423-021-00742-4","article-title":"Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy","volume":"19","author":"Huppert","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.06.005","article-title":"Metabolic regulation of Tregs in cancer: opportunities for immunotherapy","volume":"3","author":"Wang","year":"2017","journal-title":"Trends Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3322\/caac.21818","article-title":"Immunosurveillance in clinical cancer management","volume":"74","author":"Kroemer","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.031","article-title":"History, genetics, and strategies for cancer prevention in Lynch syndrome","volume":"12","author":"Kastrinos","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz441","article-title":"Effective mismatch repair depends on timely control of PCNA retention on DNA by the Elg1 complex","volume":"47","author":"Paul Solomon Devakumar","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01583-w","article-title":"Immunotherapy for microsatellite-stable metastatic colorectal cancer: can we close the gap between potential and practice","volume":"26","author":"Hamid","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00848-w","article-title":"Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma","volume":"21","author":"Klobuch","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/english\/efy035","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11523-019-00690-0","article-title":"Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond","volume":"15","author":"Cohen","year":"2020","journal-title":"Target Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1935","article-title":"Immunotherapy of MSI cancer: facts and hopes","volume":"30","author":"Wilbur","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andre","year":"2025","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andre","year":"2025","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0129","article-title":"Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"24","author":"Morse","year":"2019","journal-title":"Oncologist"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.21417\/ky2019nm","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","article-title":"Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop","volume":"184","author":"Marangoni","year":"2021","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165108","article-title":"Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis","author":"Singh","year":"2022","journal-title":"JCI Insight"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12486","article-title":"Interactions of indoleamine 2,3-dioxygenase-expressing LAMP3(+) dendritic cells with CD4(+) regulatory T cells and CD8(+) exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications","volume":"43","author":"Qu","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon gamma and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1038\/s41467-023-41737-1","article-title":"PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNgamma-driven acquired resistance in preclinical cancer models","volume":"14","author":"Wong","year":"2023","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006533","article-title":"Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies","volume":"11","author":"Anderson","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","article-title":"Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12943-024-02193-7","article-title":"Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy","volume":"23","author":"Gan","year":"2024","journal-title":"Mol Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/jci148549","article-title":"Fighting in a wasteland: deleterious metabolites and antitumor immunity","volume":"132","author":"Watson","year":"2022","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.05.012","article-title":"Organoid cultures for cancer modeling","volume":"30","author":"Yan","year":"2023","journal-title":"Cell Stem Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414376","article-title":"Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms","volume":"15","author":"Majumder","year":"2024","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127071","article-title":"Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","article-title":"Cancer stem cells and niches: challenges in immunotherapy resistance","volume":"24","author":"Pan","year":"2025","journal-title":"Mol Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.03.012","article-title":"A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers","volume":"40","author":"Hanada","year":"2022","journal-title":"Cancer Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J Immunother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-022-02264-x","article-title":"Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity","volume":"41","author":"Archilla-Ortega","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0506","article-title":"Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"B76","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-013-1021-5","article-title":"The metastasis-promoting roles of tumor-associated immune cells","volume":"91","author":"Smith","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.10.003","article-title":"An HIF-1alpha\/VEGF-A axis in cytotoxic T cells regulates tumor progression","volume":"32","author":"Palazon","year":"2017","journal-title":"Cancer Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04440-0","article-title":"Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy","volume":"149","author":"Davern","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1753180","article-title":"Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance","volume":"13","author":"Han","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013697","article-title":"Targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment\/cGAS-STING\/STAT1-mediated CXCL9\/10 in tumor microenvironment","volume":"14","author":"Wang","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.52244","article-title":"Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy in patients with metastatic colorectal cancer with measures of microsatellite instability, mismatch repair, or tumor mutational burden","volume":"6","author":"Quintanilha","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B85","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc.2015.12","article-title":"A panoply of errors: polymerase proofreading domain mutations in cancer","volume":"16","author":"Rayner","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907147106","article-title":"DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice","volume":"106","author":"Albertson","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B87","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/POLD1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025631118","article-title":"TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment","volume":"118","author":"Maddalena","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01945-y","article-title":"Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types","volume":"42","author":"Gurung","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22861","article-title":"Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF\/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions","volume":"59","author":"Vankova","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2024.02.010","article-title":"ARID1A orchestrates SWI\/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis","volume":"42","author":"Barisic","year":"2024","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ng.3744","article-title":"ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice","volume":"49","author":"Mathur","year":"2017","journal-title":"Nat Genet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-3231","article-title":"ARID1A mediates SWI\/SNF-independent maintenance of heterochromatin architecture to restrain viral mimicry and immunogenicity in colon cancer","volume":"86","author":"Li","year":"2026","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1053\/j.gastro.2021.10.010","article-title":"HLA class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability","volume":"162","author":"Kawazu","year":"2022","journal-title":"Gastroenterology"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/jci143296","article-title":"Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response","volume":"131","author":"von Locquenghien","year":"2021","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1038\/s41467-021-27620-x","article-title":"Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response","volume":"12","author":"Yen","year":"2021","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.022","article-title":"Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability\/DNA mismatch repair deficiency","volume":"86","author":"Cohen","year":"2017","journal-title":"Eur J Cancer"},{"key":"B100","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","article-title":"Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside","volume":"13","author":"Yin","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166860","article-title":"Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: current research and future perspective","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01197","article-title":"Cancer cell metabolism bolsters immunotherapy resistance by promoting an immunosuppressive tumor microenvironment","volume":"10","author":"Jiang","year":"2020","journal-title":"Front Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112767","article-title":"TGF-beta-mediated epithelial-mesenchymal transition and cancer metastasis","volume":"20","author":"Hao","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","article-title":"TGF-beta, EMT, and resistance to anti-cancer treatment","volume":"97","author":"Wang","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41525-021-00169-w","article-title":"Ratio of the interferon-gamma signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma","volume":"6","author":"Cui","year":"2021","journal-title":"NPJ Genom Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40364-021-00327-3","article-title":"Next frontier in tumor immunotherapy: macrophage-mediated immune evasion","volume":"9","author":"Qiu","year":"2021","journal-title":"biomark Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12967-024-05409-y","article-title":"Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response","volume":"22","author":"Sadeghirad","year":"2024","journal-title":"J Transl Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.03.009","article-title":"Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade","volume":"41","author":"Pai","year":"2023","journal-title":"Cancer Cell"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion'","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1172\/jci154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci Adv"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0824","article-title":"Of context, quality, and complexity: fine-combing tumor mutational burden in immunotherapy-treated cancers","volume":"31","author":"Niknafs","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12967-025-06993-3","article-title":"GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients","volume":"23","author":"Broche","year":"2025","journal-title":"J Transl Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.04.025","article-title":"Pharmacomicrobiomics: the role of the gut microbiome in immunomodulation and cancer therapy","volume":"168","author":"Bolte","year":"2025","journal-title":"Gastroenterology"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2423024","article-title":"Intestinal flora: a potential pathogenesis mechanism and treatment strategy for type 1 diabetes mellitus","volume":"16","author":"Huang","year":"2024","journal-title":"Gut Microbes"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00908-9","article-title":"Exploiting bacteria for cancer immunotherapy","volume":"21","author":"Kwon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i2.375","article-title":"Microbiome and colorectal carcinogenesis: linked mechanisms and racial differences","volume":"14","author":"Tortora","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-4378","article-title":"Dietary fiber lacks a consistent effect on immune checkpoint blockade efficacy across diverse murine tumor models","volume":"85","author":"Roichman","year":"2025","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-00966-0","article-title":"The individual response to antibiotics and diet - insights into gut microbial resilience and host metabolism","volume":"20","author":"Vliex","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.04.023","article-title":"Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip","volume":"77","author":"Qiao","year":"2025","journal-title":"J Adv Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2514144","article-title":"Bacteria enable tolerance to bile salt exposure in an immune-competent human intestinal model","volume":"17","author":"Li","year":"2025","journal-title":"Gut Microbes"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101754","article-title":"Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology","volume":"67","author":"Jamal","year":"2023","journal-title":"Semin Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00987-1","article-title":"Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity","volume":"20","author":"Kim","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01183-w","article-title":"Gut microbiota-derived short-chain fatty acids and their role in human health and disease","volume":"23","author":"Mukhopadhya","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101355","article-title":"Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy","volume":"5","author":"Cheng","year":"2024","journal-title":"Cell Rep Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/gutjnl-2020-321747","article-title":"Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health","volume":"70","author":"Fassarella","year":"2021","journal-title":"Gut"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13785","article-title":"A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: multi-pathway combination therapy with PD-1\/PD-L1 inhibitors","volume":"173","author":"Cai","year":"2024","journal-title":"Immunology"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-024-44795-1","article-title":"Macro CD5L(+) deteriorates CD8(+)T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma","volume":"15","author":"Lu","year":"2024","journal-title":"Nat Commun"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adm8660","article-title":"Targeting conserved TIM3(+)VISTA(+) tumor-associated macrophages overcomes resistance to cancer immunotherapy","volume":"10","author":"Vanmeerbeek","year":"2024","journal-title":"Sci Adv"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B153","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3226","article-title":"IFNgamma signaling in natural and therapy-induced antitumor responses","volume":"28","author":"Martinez-Sabadell","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05593-1","article-title":"Gammadelta T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc6424","article-title":"Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape","volume":"6","author":"Takeuchi","year":"2021","journal-title":"Sci Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci Transl Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115432","article-title":"The tumor microenvironment is an ecosystem sustained by metabolic interactions","volume":"44","author":"Kay","year":"2025","journal-title":"Cell Rep"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02318-7","article-title":"Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges","volume":"129","author":"Parra","year":"2023","journal-title":"Br J Cancer"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02848-8","article-title":"DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors","volume":"131","author":"Amodio","year":"2024","journal-title":"Br J Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B164","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-024-01011-y","article-title":"Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors","volume":"46","author":"Spiga","year":"2024","journal-title":"Semin Immunopathol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"B170","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027674","article-title":"Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma","volume":"146","author":"Giri","year":"2025","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-1943","article-title":"Longitudinal profiling of circulating tumor DNA reveals the evolutionary dynamics of metastatic prostate cancer during serial therapy","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial","volume":"9","author":"Taieb","year":"2023","journal-title":"JAMA Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.019","article-title":"Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial","volume":"53","author":"Taieb","year":"2021","journal-title":"Dig Liver Dis"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.218","article-title":"A phase II study of avelumab monotherapy in patients with mismatch repair-deficient\/microsatellite instability-high or POLE-mutated metastatic or unresectable colorectal cancer","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andre","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.03.03","article-title":"Tislelizumab in previously treated, locally advanced unresectable\/metastatic microsatellite instability-high\/mismatch repair-deficient solid tumors","volume":"36","author":"Li","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101302","article-title":"Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma","volume":"4","author":"Duan","year":"2023","journal-title":"Cell Rep Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-011-9449-7","article-title":"Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer","volume":"10","author":"Bauer","year":"2011","journal-title":"Fam Cancer"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3390\/life14081015","article-title":"The role of brassinosteroids in plant cold stress response","volume":"14","author":"He","year":"2024","journal-title":"Life (Basel)"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.137365","article-title":"Importance of lymph node immune responses in MSI-H\/dMMR colorectal cancer","volume":"6","author":"Inamori","year":"2021","journal-title":"JCI Insight"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156617","article-title":"Increased IL-22 in cerebrospinal fluid of neuro-behcet's disease patients","volume":"179","author":"Belghith","year":"2024","journal-title":"Cytokine"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2025.107435","article-title":"Decoding the interaction of an imidazo-pyrimidine derivative with serum proteins: spectroscopic, computational and structure-activity relationship analysis","volume":"322","author":"Chakraborty","year":"2025","journal-title":"Biophys Chem"},{"key":"B188","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00203-024-03931-7","article-title":"Metabolomic and genomic insights into TMA degradation by a novel halotolerant strain - Paracoccus sp. PS1","volume":"206","author":"Seth","year":"2024","journal-title":"Arch Microbiol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10653-024-02195-w","article-title":"Spraying or fertigation? Looking for the better method in terms of the lower concentration of Pb and Ni in greenhouse cucumber","volume":"46","author":"Mousavi","year":"2024","journal-title":"Environ Geochem Health"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1007\/s10265-023-01512-1","article-title":"The PpMYB75-PpDFR module reveals the difference between 'SR' and its bud variant 'RMHC' in peach red flesh","volume":"137","author":"Xu","year":"2024","journal-title":"J Plant Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828717\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:06:20Z","timestamp":1782918380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828717\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":191,"alternative-id":["10.3389\/fimmu.2026.1828717"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1828717","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1828717"}}